|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02096 SIMCERE PHARMA
Nominal 
12.060 +0.880 (+7.871%) Profitability Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| ROAA (%) | 10.211% | 6.431% | 6.605% | 8.887% | 14.282% |
| ROAE (%) | 16.250% | 10.058% | 9.959% | 13.721% | 25.677% |
| Return on Capital Employed (%) | 11.810% | 8.139% | 8.751% | 11.900% | 21.235% |
Margin Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Gross Profit Margin (%) | 81.613% | 80.247% | 75.428% | 79.010% | 78.399% |
| EBITDA Margin (%) | 25.045% | 17.699% | 15.457% | 18.094% | 34.009% |
| Pre-tax Profit Margin (%) | 19.587% | 12.188% | 11.199% | 14.014% | 28.038% |
| Net Profit Margin (%) | 17.384% | 10.881% | 10.817% | 14.719% | 30.144% |
Liquidity Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Current Ratio (X) | 2.209 X | 2.013 X | 2.099 X | 1.840 X | 1.625 X |
| Quick Ratio (X) | 2.033 X | 1.795 X | 1.871 X | 1.737 X | 1.549 X |
Leverage Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Total Liabilities / Total Assets(%) | 36.067% | 38.500% | 33.453% | 33.749% | 36.397% |
| Total Debt / Total Assets (%) | 8.060% | 10.426% | 13.168% | 13.966% | 16.099% |
| Net Debt / Total Assets (%) | -15.790% | -6.407% | -5.325% | -1.405% | 6.522% |
| Total Debt / Shareholders' Funds (%) | 12.616% | 16.952% | 19.788% | 21.127% | 25.414% |
| Long Term Debt / Shareholders' Funds (%) | 0.820% | 1.271% | 4.628% | 2.186% | 1.153% |
| Net Debt / Shareholders' Funds (%) | -24.715% | -10.418% | -8.002% | -2.125% | 10.296% |
| Net Cash / (Debt) ($) | 2.325B | 743.217M | 577.938M | 151.568M | (662.743M) |
| Net Cash / (Debt) per share ($) | 0.896 | 0.294 | 0.220 | 0.057 | (0.252) |
| Total Debt / Capital Employed (%) | 10.429% | 13.633% | 17.498% | 19.262% | 23.049% |
| Interest Coverage Ratio (X) | 16.807 X | 12.627 X | 22.408 X | 26.757 X | 20.786 X |
Efficiency Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Inventory Turnover (Day) | 151.908 Day | 168.255 Day | 103.335 Day | 74.234 Day | 84.125 Day |
| Receivables Turnover (Day) | 130.731 Day | 146.641 Day | 137.279 Day | 136.717 Day | 155.856 Day |
| Payables Turnover (Day) | 12.395 Day | 16.318 Day | 18.025 Day | 19.028 Day | 20.661 Day |
| Remarks: | Real time quote last updated: 27/03/2026 12:04 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,344,008 |
| %Change | 86.150% |
| EPS / (LPS) | RMB 0.540 |
| NBV Per Share (¥) | RMB 3.624 |